Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib

A large number of EGFR mutant non‐small cell lung cancer patients primordially benefit from first‐line treatment with first‐generation EGFR‐tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. However, multiple acquired resistance mechanisms have been described that limit the clinical...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Tang, Kejing, Jiang, Neng, Kuang, Yukun, He, Qiong, Li, Shuhua, Luo, Jiping, Jiang, Wenting, Chen, Yangshan, Sun, Yu, Chen, Lili, Chen, Yanyang, Zhu, Junfeng, Cui, Yongmei, Wan, Han, Ke, Zunfu
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2018
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360229/
https://ncbi.nlm.nih.gov/pubmed/30521113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12927
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados